Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated polyneuropathy characterized by symmetric weakness of proximal and distal muscles and by progression continuing > 2 mo.
Symptoms resemble those of Guillain-Barré syndrome (see Guillain-Barré Syndrome (GBS)). However, progression for > 2 mo differentiates CIDP from Guillain-Barré syndrome, which is monophasic and self-limited. CIDP develops in 3 to 10% of patients with Guillain-Barré syndrome.
Testing includes CSF analysis and electrodiagnostic tests. Results are similar to those in Guillain-Barré syndrome, including albuminocytologic dissociation (increased protein but normal WBC count) and demyelination, detected by electrodiagnostic testing. Nerve biopsy, which can also detect demyelination, is seldom needed.
Unlike Guillain-Barré syndrome, CIDP responds to corticosteroids. However, in severe or rapidly progressive cases, plasma exchange or IVIG may be preferred. Immunosuppressants (eg, azathioprine) may be helpful and can reduce corticosteroid dependence. Treatment may be needed for a long time.
Last full review/revision March 2014 by Michael Rubin, MDCM
Content last modified March 2014